Suchergebnisse

Order signed: David Cameron, C.J. ; Title taken from the text. ; At head of title: Supplement to the Government gazette of 15th May, 1860. ; Mode of access: Internet.

BACKGROUND: The Veterans Health Administration's system for documenting self-directed violence (SDV) requires that clinicians make a determination of the suicidal intent of the behavior (ie, "undetermined" intent vs. "suicide attempt") which contributes to the enhanced care offered. Past studies suggest clinicians' judgment of suicide risk is impacted by patient demographics regardless of clinical presentation. As women are less likely to die by suicide than men, women's SDV may be taken less seriously; they may be more likely to have their SDV classified as "undetermined" than men, which may impact the care received. OBJECTIVES: This study examines whether women veterans' SDV is disproportionately classified as "undetermined" suicidal intent versus "suicide attempt" as compared with men veterans, and how one's classification and gender modifies the care received. RESEARCH DESIGN: This was an observational, retrospective study of data from Veterans Health Administration administrative databases. We included all veterans with documented nonfatal "undetermined" SDV events and "suicide attempts" between 2013 and 2018 (N = 55,878). Objectives were evaluated using mixed-effects logistic regression models. RESULTS: Women veterans were disproportionately more likely than men veterans to have SDV classified as "undetermined" (odds ratio = 1.17; 95% confidence interval, 1.08–1.27). Veterans who received an "undetermined" classification were significantly less likely to receive enhanced care. However, this relationship was not moderated by gender. CONCLUSIONS: Gender may impact clinicians' determinations of intent of SDV, but more research is needed on the extent of classification biases and to understand causes. Further, classification of intent is critical, as there is a strong relationship between classification and enhanced care.

"La publication de recueils à l'occasion des anniversaires de la fédération canadienne est une tradition. En 1917, et de nouveau en 1967, des chercheurs ont publié des ouvrages sur la formation de la fédération canadienne et ses perspectives d'avenir. Ces recueils ont toutefois été publiés en anglais ou en français. À l'occasion du 150e anniversaire de la fédération canadienne, des chercheurs des Universités de Toronto et de York ont réuni les meilleurs articles et chapitres de livres portant sur la Confédération rédigés dans l'une ou l'autre des langues officielles. Vingt-neuf articles ont été traduits en anglais ou en français pour la première fois. De plus, ce recueil a élargi les horizons des débats portant sur 1867 en incluant des textes sur les autochtones. Alors que le pays chemine vers 2067, les Canadiens doivent comprendre et défier les discours traditionnels qui ont influencé la trame narrative du pays. Ce recueil interdisciplinaire en deux tomes, publié intégralement en français et en anglais, est un pas dans cette direction".--Back cover

BACKGROUND: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter assays that measure the expression of several tumour genes simultaneously have been developed to guide the use of adjuvant chemotherapy for this breast cancer subtype. The assays provide prognostic information and have been claimed to predict chemotherapy sensitivity. There is a dearth of prospective validation studies. The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) is the feasibility phase of a randomised controlled trial (RCT) designed to validate the use of multiparameter assay directed chemotherapy decisions in the NHS. OBJECTIVES: OPTIMA prelim was designed to establish the acceptability to patients and clinicians of randomisation to test-driven treatment assignment compared with usual care and to select an assay for study in the main RCT. DESIGN: Partially blinded RCT with adaptive design. SETTING: Thirty-five UK hospitals. PARTICIPANTS: Patients aged ≥ 40 years with surgically treated ER-positive HER2-negative primary breast cancer and with 1-9 involved axillary nodes, or, if node negative, a tumour at least 30 mm in diameter. INTERVENTIONS: Randomisation between two treatment options. Option 1 was standard care consisting of chemotherapy followed by endocrine therapy. In option 2, an Oncotype DX(®) test (Genomic Health Inc., Redwood City, CA, USA) performed on the resected tumour was used to assign patients either to standard care [if 'recurrence score' (RS) was > 25] or to endocrine therapy alone (if RS was ≤ 25). Patients allocated chemotherapy were blind to their randomisation. MAIN OUTCOME MEASURES: The pre-specified success criteria were recruitment of 300 patients in no longer than 2 years and, for the final 150 patients, (1) an acceptance rate of at least 40%; (2) recruitment taking no longer than 6 months; and (3) chemotherapy starting within 6 weeks of consent in at least 85% of patients. RESULTS: Between September 2012 and 3 June 2014, 350 patients consented to join OPTIMA prelim and 313 were randomised; the final 150 patients were recruited in 6 months, of whom 92% assigned chemotherapy started treatment within 6 weeks. The acceptance rate for the 750 patients invited to participate was 47%. Twelve out of the 325 patients with data (3.7%, 95% confidence interval 1.7% to 5.8%) were deemed ineligible on central review of receptor status. Interviews with researchers and recordings of potential participant consultations made as part of the integral qualitative recruitment study provided insights into recruitment barriers and led to interventions designed to improve recruitment. Patient information was changed as the result of feedback from three patient focus groups. Additional multiparameter analysis was performed on 302 tumour samples. Although Oncotype DX, MammaPrint(®)/BluePrint(®) (Agendia Inc., Irvine, CA, USA), Prosigna(®) (NanoString Technologies Inc., Seattle, WA, USA), IHC4, IHC4 automated quantitative immunofluorescence (AQUA(®)) [NexCourse BreastTM (Genoptix Inc. Carlsbad, CA, USA)] and MammaTyper(®) (BioNTech Diagnostics GmbH, Mainz, Germany) categorised comparable numbers of tumours into low- or high-risk groups and/or equivalent molecular subtypes, there was only moderate agreement between tests at an individual tumour level (kappa ranges 0.33-0.60 and 0.39-0.55 for tests providing risks and subtypes, respectively). Health economics modelling showed the value of information to the NHS from further research into multiparameter testing is high irrespective of the test evaluated. Prosigna is currently the highest priority for further study. CONCLUSIONS: OPTIMA prelim has achieved its aims of demonstrating that a large UK clinical trial of multiparameter assay-based selection of chemotherapy in hormone-sensitive early breast cancer is feasible. The economic analysis shows that a trial would be economically worthwhile for the NHS. Based on the outcome of the OPTIMA prelim, a large-scale RCT to evaluate the clinical effectiveness and cost-effectiveness of multiparameter assay-directed chemotherapy decisions in hormone-sensitive HER2-negative early breast would be appropriate to take place in the NHS. TRIAL REGISTRATION: Current Controlled Trials ISRCTN42400492. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 10. See the NIHR Journals Library website for further project information. The Government of Ontario funded research at the Ontario Institute for Cancer Research. Robert C Stein received additional support from the NIHR University College London Hospitals Biomedical Research Centre.